Serum concentrations of the interferon-γ-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease
Ferdinando Nicoletti(University of Catania), Ramón Gomis(Universitat de Barcelona), Ignacio Conget(Universitat de Barcelona), Roberto Di Marco(University of Catania), Klaus Bendtzen(Rigshospitalet), Angela Messina(University of Catania), M Mazzarino(University of Catania), M. Di Mauro(University of Catania)
Cited by 170
Related Papers
Natural products in drug discovery: advances and opportunities
|Nature Reviews Drug Discovery|2021|5.2k
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
|Oncotarget|2011|579
GSK-3 as potential target for therapeutic intervention in cancer
|Oncotarget|2014|508
The neuropathic pain: An overview of the current treatment and future therapeutic approaches
|International Journal of Immunopathology and Pharmacology|2019|495